NOVEOME BIOTHERAPEUTICS INC

NOVEOME BIOTHERAPEUTICS INC specializes in the research, development, and clinical translation of novel biologic therapeutics, with a focus on regenerative medicine and tissue repair technologies. The company leverages proprietary platform technologies to engineer biologically active molecules and cell-based formulations designed to modulate inflammatory pathways and promote healing in chronic and acute conditions. Core technical expertise includes protein engineering, recombinant biologics development, preclinical pharmacology, and GMP-compliant manufacturing processes for advanced therapeutic products. Their differentiation lies in the application of targeted bioactive proteins to restore tissue function, particularly in gastrointestinal, dermatological, and wound healing indications, with a strong emphasis on mechanism-driven therapeutic design. Award history is not available to infer specific agency relationships or programmatic engagements. Consequently, no definitive patterns can be established regarding federal partnerships or the nature of government-funded work. The primary NAICS code 325414 corresponds to Pharmaceutical and Medicine Manufacturing, indicating the company operates within the biopharmaceutical production sector. In practice, this means the organization develops and scales biologic drugs under FDA regulatory frameworks, focusing on novel molecular entities rather than small-molecule pharmaceuticals. The market positioning is that of a niche biotech innovator advancing next-generation biologics with potential applications in both clinical and government-funded biomedical research initiatives. NOVEOME BIOTHERAPEUTICS INC is structured as a small business (2L entity) headquartered in Pittsburgh, Pennsylvania. The company holds no federal certifications such as 8(a), HUBZone, or WOSB. Its government market presence is not discernible from available award data, but its technical profile suggests alignment with NIH, DoD, and VA research priorities in regenerative medicine and trauma recovery. The organization maintains a focused, R&D-driven operational model centered on proprietary biologic platforms.